title: COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.
abstract: Berberine is an isoquinoline alkaloid that has several pharmacological effects such as antiinflammatory, antimicrobial, apoptosis-inducing and anticancer effects. It has been illustrated that the antiinflammatory effect is mediated by suppressing the nuclear factor-kappa B (NF-κB) that activates expression of some antiinflammatory and antiapoptotic proteins including cyclooxygenase-2(COX-2), inducible nitric oxide synthase (iNOS) and survivin; therefore, berberine may induce apoptosis by reducing antiinflammatory and antiapoptotic agents, which suggest the relationship between antiinflammatory and apoptosis pathways. For further illustration of the mechanism of berberine action, the human ductal breast epithelial tumor cell line (T47D cell line) was treated with different concentrations of berberine (25-100 μM/ml). Berberine in 50 μM/ml had the most reducing effect on cell viability and inducing of apoptosis. The level of COX-2, iNOS and survivin proteins decreased in berberine-treated cells; however, treatment of the cells with aspirin and aminoguanidine (AG), COX-2 and iNOS inhibitors, respectively, showed that despite the cell growth-reducing effect of aspirin, AG did not have a significant effect on cell viability. On the other hand, with the attention to reduction in survivin protein level in berberine-treated cells, the results suggest that the apoptotic effect of berberine may be mediated by reduction in both of the COX-2 and survivin in T47D cell line, while the iNOS does not play any effective role in berberine-induced apoptosis.
authors.affiliation: Department of Biology, Urmia Branch, Islamic Azad University, Urmia, Iran.
authors.forename: Yaghub
authors.initials: Y
authors.lastname: Pazhang
authors.forename: Shahin
authors.initials: S
authors.lastname: Ahmadian
authors.forename: Nader
authors.initials: N
authors.lastname: Javadifar
authors.forename: Mahshid
authors.initials: M
authors.lastname: Shafiezadeh
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001241:Aspirin / Q000494:pharmacology; D001599:Berberine / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D005260:Female; D006146:Guanidines / Q000494:pharmacology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors*; D000077022:Survivin
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D006146:Guanidines; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D001599:Berberine; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D001241:Aspirin; C004479:pimagedine
references.citation: J Surg Oncol. 1999 Apr;70(4):222-9
references.pmid: 10219017
references.citation: Br J Cancer. 2001 Feb 2;84(3):335-9
references.pmid: 11161397
references.citation: Trends Mol Med. 2002 Aug;8(8):385-9
references.pmid: 12127724
references.citation: Cancer Res. 2008 Jul 1;68(13):5370-9
references.pmid: 18593939
references.citation: Life Sci. 2006 Jul 24;79(9):870-6
references.pmid: 16616209
references.citation: Cancer Res. 1998 Jan 15;58(2):334-41
references.pmid: 9443414
references.citation: Cell Biol Int. 2011 Aug;35(8):757-65
references.pmid: 21391919
references.citation: Cancer Res. 2001 Oct 1;61(19):7305-9
references.pmid: 11585770
references.citation: J Physiol Pharmacol. 2005 Sep;56 Suppl 5:57-73
references.pmid: 16247189
references.citation: Am J Pathol. 2003 Mar;162(3):793-801
references.pmid: 12598314
references.citation: Br J Cancer. 2006 Jan 30;94(2):253-8
references.pmid: 16421596
references.citation: Cancer Lett. 1995 Jul 13;93(2):193-200
references.pmid: 7621428
references.citation: Mol Cell Biochem. 2006 Oct;290(1-2):205-9
references.pmid: 16924421
references.citation: Br J Cancer. 1995 Jul;72(1):41-4
references.pmid: 7541238
references.citation: Carcinogenesis. 2000 Feb;21(2):139-46
references.pmid: 10657949
references.citation: Carcinogenesis. 2009 Mar;30(3):377-86
references.pmid: 19136477
references.citation: Cancer Lett. 2007 Apr 28;249(1):49-60
references.pmid: 17275177
references.citation: Cancer Treat Rev. 2009 Nov;35(7):553-62
references.pmid: 19559538
references.citation: Mol Cancer Ther. 2003 Aug;2(8):815-23
references.pmid: 12939472
references.citation: Ann Thorac Surg. 2002 Nov;74(5):1648-52
references.pmid: 12440624
references.citation: Cancer Metastasis Rev. 1998 Mar;17(1):1-6
references.pmid: 9544419
references.citation: Cell. 1994 Sep 23;78(6):915-8
references.pmid: 7522969
references.citation: APMIS. 2010 Feb;118(2):115-24
references.pmid: 20132175
references.citation: Eur J Cancer. 1979 May;15(5):659-70
references.pmid: 228940
references.citation: FEBS Lett. 1998 Aug 14;433(1-2):125-31
references.pmid: 9738946
references.citation: Gen Pharmacol. 1997 Nov;29(5):697-700
references.pmid: 9347312
references.citation: Annu Rev Biochem. 2000;69:145-82
references.pmid: 10966456
references.citation: Arch Toxicol. 2006 Feb;80(2):62-73
references.pmid: 16189662
references.citation: World J Gastroenterol. 2006 Jan 7;12(1):21-8
references.pmid: 16440412
references.citation: World J Gastroenterol. 2005 Jul 7;11(25):3830-3
references.pmid: 15991277
references.citation: World J Gastroenterol. 2009 Mar 7;15(9):1065-71
references.pmid: 19266598
references.citation: Med Res Rev. 2011 Mar;31(2):161-201
references.pmid: 19967720
references.citation: J Ethnopharmacol. 2009 Oct 29;126(1):5-17
references.pmid: 19686830